Study design
Between 22 November 2016 and 24 January 2020, 742 patients were screened for eligibility with 525 randomised to one of the 6 possible treatment orders for the three therapies and asked to take each therapy for 16 weeks. HbA1c, weight, participant’s experience of the therapy, and side effects were recorded at the end of each treatment period. The 16-week treatment period was designed to allow an “on-treatment” washout for the first month, with each end-of-period HbA1c reflecting the previous 8-12 weeks on therapy. HbA1c results were only considered valid if the participant had been on the therapy for at least 12 weeks and they had at least 80% adherence, as measured by pill count at the end of each treatment period. Participants reported whether they had experienced any of a pre-defined list of 16 side effects associated with the three therapies (see 